Actimed Therapeutics
Financials
Estimates*
EUR | 2018 | 2019 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Revenues | - | - | 1.7m | <1m | <1m |
% growth | - | - | - | (44 %) | (55 %) |
EBITDA | (<1m) | (<1m) | (1.2m) | (5.5m) | - |
% EBITDA margin | - | - | (69 %) | (576 %) | - |
Profit | (<1m) | (<1m) | (<1m) | (4.3m) | - |
% profit margin | - | - | (48 %) | (448 %) | - |
R&D budget | - | <1m | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
* | N/A | £1.3m | Seed |
N/A | £2.5m | Seed | |
* | £5.0m | Seed | |
* | £5.0m | Series A | |
* | £4.8m Valuation: £25.0m 31.3x EV/LTM Revenues -5.4x EV/LTM EBITDA | Series A | |
* | £1.0m Valuation: £77.5m 97.2x EV/LTM Revenues -16.9x EV/LTM EBITDA | Early VC | |
Total Funding | €23.5m |
Recent News about Actimed Therapeutics
EditActimed Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for cachexia, a debilitating wasting disease associated with cancer and other serious chronic illnesses. The company aims to transform care for this underserved and vulnerable patient population by prolonging and improving their quality of life, restoring their dignity, and easing the burden for patients, carers, and healthcare providers. Actimed Therapeutics operates in the global biopharmaceutical market, focusing on research and development to bring new therapeutic options to market. The business model is centered around advancing programs from scientific research through clinical development, regulatory approval, and into healthcare systems worldwide. Revenue is generated through the development and commercialization of pharmaceutical products designed to treat cachexia. The company serves patients suffering from cancer-related cachexia and other chronic illnesses, healthcare providers, and caregivers.
Keywords: cachexia, biopharmaceutical, cancer, chronic illness, innovation, quality of life, clinical development, regulatory approval, healthcare, therapeutic.